GreenLight Biosciences and Samsung Biologics announce collaboration

The partnership will help advance GreenLight’s messenger RNA COVID-19 vaccine candidate, in support of ongoing global health needs.

 GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced a partnership agreement in which Samsung Biologics will manufacture GreenLight’s messenger RNA COVID-19 vaccine candidate at commercial scale.

Further information can be found in the full press release.